# Akamai Technologies

Type: Company (AKAM)

Source: GetYourBrief — https://getyourbrief.com/entity/akamai-technologies
Canonical HTML page: https://getyourbrief.com/entity/akamai-technologies

## Timeline

- **2026-08-06**: Akamai and AvePoint report Q2 2026 earnings — Both companies released their quarterly results, highlighting AI-driven demand for infrastructure and security.
- **2026-07**: AvePoint launches standalone AgentPulse product — AgentPulse, previously bundled in the Control suite, became available as a standalone product to provide visibility into AI agent ownership, permissions, and costs.

## Recent coverage (7 stories, network-wide)

### Akamai Guides FY EPS to $6.40-$7.05, But Stock Drops 3%
2026-08-07 03:12:01 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Akamai Technologies boosted its full-year EPS guidance far above analyst estimates, but shares fell 3% as revenue guidance merely met expectations and valuation concerns weighed. The Q2 earnings beat and strong balance sheet provide support, yet the rich P/E and moderate growth rate leave investors cautious.
Full story: https://getfinancebrief.com/story/akamai-fy2026-guidance-stock-drop

### AI Agent Sprawl: AvePoint’s 88% Incident Rate and Akamai’s $600M Robotics Cloud Deal
2026-08-07 01:03:26 · Sector: ai · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Q2 earnings of AvePoint and Akamai reveal two sides of enterprise AI: AvePoint’s survey found 88% of IT leaders hit by AI agent security incidents, while Akamai landed a $600 million cloud infrastructure deal for robotics development. Both signal a maturing but chaotic AI market.
Full story: https://getaibrief.com/story/ai-avepoint-agent-sprawl-akamai-robotics-cloud-deal

### AvePoint SaaS Revenue Hits $98.5M (+27%); Akamai Cloud Grows 5% Amid $2.8B Backlog
2026-08-07 01:01:47 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AvePoint's SaaS revenue surged 27% to $98.5 million, now 79% of total, while Akamai's cloud infrastructure revenue rose 5% and its multi-year commitments swelled to $2.8 billion. The Q2 results underscore diverging SaaS and IaaS models in the AI era.
Full story: https://getsaasbrief.com/story/saas-avepoint-akamai-earnings-saas-cloud-growth

### Akamai’s $2.8B Cloud Stack & AvePoint’s 27% ARR Surge Drive Q2 Valuations
2026-08-07 01:00:38 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Akamai Technologies locked in over $2.8 billion in multi-year cloud commitments in 2026 so far, while AvePoint's ARR jumped 27% to $465.1 million. Both companies' Q2 results highlight how AI infrastructure and governance are reshaping growth and margin profiles.
Full story: https://getfinancebrief.com/story/finance-akamai-avepoint-earnings-2-8b-cloud-commitments

### 88% of IT Leaders Hit by AI Agent Security Incidents: Akamai & AvePoint Earnings React
2026-08-07 00:59:26 · Sector: cyber · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AvePoint's Q2 survey revealed 88% of 750 IT leaders suffered AI agent security incidents, just as Akamai ramps cloud infrastructure to power AI workloads. Both companies' earnings show surging demand for security and governance in an era of agent sprawl.
Full story: https://getcyberbrief.com/story/cyber-akamai-avepoint-ai-security-incidents-88-percent

### Invenomic Capital Exits $24M Haemonetics Stake Amid MedTech Underperformance
2026-03-21 01:09:37 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker. The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.
Full story: https://getbiobrief.com/story/invenomic-capital-exits-haemonetics-stake-medtech-underperformance

### Invenomic Capital Exits $24M Haemonetics Stake Amid Med-Tech Underperformance
2026-03-21 01:09:03 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, a leader in blood and plasma management technology. The exit comes as the stock underperformed the broader market by 25% over the past year, signaling a shift in institutional sentiment toward the medical device sector.
Full story: https://gethealthbrief.com/story/invenomic-capital-exits-haemonetics-stake

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.